Fund shareholders of Context Therapeutics Inc
ISIN US21077P1084 · United States
- Fund shareholders
- 10
- Of which ETFs
- 1 9 other funds
- Value held
- 13.4M $
- Share of capital
- 5.8 % of 91.9M shares on Aug 3, 2026
| Fund | Shares | Value | Weight in fund | Share of capital | |
|---|---|---|---|---|---|
| VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS | 2,815,486 | 7.4M $ | 0.00 % | 3.06 % | as of Mar 31, 2026 ↗ |
| Franklin Biotechnology Discovery Fund Franklin Strategic Series | 1,398,833 | 3.3M $ | 0.32 % | 1.52 % | as of Apr 30, 2026 ↗ |
| VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS | 520,898 | 1.4M $ | 0.00 % | 0.57 % | as of Mar 31, 2026 ↗ |
| Fidelity Extended Market Index Fund Fidelity Concord Street Trust | 247,735 | 557.4K $ | 0.00 % | 0.27 % | as of Feb 28, 2026 ↗ |
| Fidelity Total Market Index Fund Fidelity Concord Street Trust | 97,615 | 219.6K $ | 0.00 % | 0.11 % | as of Feb 28, 2026 ↗ |
| Fidelity Series Total Market Index Fund Fidelity Concord Street Trust | 70,420 | 158.4K $ | 0.00 % | 0.08 % | as of Feb 28, 2026 ↗ |
| Fidelity Nasdaq Composite Index Fund Fidelity Concord Street Trust | 63,705 | 143.3K $ | 0.00 % | 0.07 % | as of Feb 28, 2026 ↗ |
| VANGUARD INSTITUTIONAL TOTAL STOCK MARKET INDEX FUND VANGUARD INSTITUTIONAL INDEX FUNDS | 53,125 | 139.2K $ | 0.00 % | 0.06 % | as of Mar 31, 2026 ↗ |
| VANGUARD BALANCED INDEX FUND VANGUARD VALLEY FORGE FUNDS | 42,444 | 111.2K $ | 0.00 % | 0.05 % | as of Mar 31, 2026 ↗ |
| Avantis U.S. Small Cap Equity ETF American Century ETF Trust | 26,383 | 59.4K $ | 0.00 % | 0.03 % | as of Feb 28, 2026 ↗ |
The funds most exposed to it
The weight is the share of a fund's net assets. The holders table counts shares; this one measures what the company weighs inside each fund.
| Fund | Weight in fund | |
|---|---|---|
| Franklin Biotechnology Discovery Fund Franklin Strategic Series | 0.32 % | as of Apr 30, 2026 ↗ |
| Avantis U.S. Small Cap Equity ETF American Century ETF Trust | 0.00 % | as of Feb 28, 2026 ↗ |
| VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS | 0.00 % | as of Mar 31, 2026 ↗ |
| Fidelity Extended Market Index Fund Fidelity Concord Street Trust | 0.00 % | as of Feb 28, 2026 ↗ |
| Fidelity Nasdaq Composite Index Fund Fidelity Concord Street Trust | 0.00 % | as of Feb 28, 2026 ↗ |
| VANGUARD INSTITUTIONAL TOTAL STOCK MARKET INDEX FUND VANGUARD INSTITUTIONAL INDEX FUNDS | 0.00 % | as of Mar 31, 2026 ↗ |
| VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS | 0.00 % | as of Mar 31, 2026 ↗ |
| Fidelity Series Total Market Index Fund Fidelity Concord Street Trust | 0.00 % | as of Feb 28, 2026 ↗ |
| Fidelity Total Market Index Fund Fidelity Concord Street Trust | 0.00 % | as of Feb 28, 2026 ↗ |
| VANGUARD BALANCED INDEX FUND VANGUARD VALLEY FORGE FUNDS | 0.00 % | as of Mar 31, 2026 ↗ |
Quarter after quarter
Each SEC quarterly data set, newest first. The change is read against the quarter before it.
| Quarter | Shareholders | Change | Shares | Change |
|---|---|---|---|---|
| 2026Q2 | 10 | +1 | 5,336,644 | -1.0 % |
| 2026Q1 | 9 | 0 | 5,391,727 | +3.5 % |
| 2025Q4 | 9 | 0 | 5,207,768 | -2.6 % |
| 2025Q3 | 9 | 0 | 5,345,363 | +2.1 % |
| 2025Q2 | 9 | 0 | 5,234,253 | +0.4 % |
| 2025Q1 | 9 | 0 | 5,211,612 | -7.2 % |
| 2024Q4 | 9 | 0 | 5,617,978 | +21.4 % |
| 2024Q3 | 9 | +3 | 4,628,455 | +478.8 % |
| 2024Q2 | 6 | 0 | 799,707 | +0.7 % |
| 2024Q1 | 6 | 0 | 794,144 | -0.9 % |
| 2023Q4 | 6 | 801,757 |
Institutional managers
56 managers declare this company to the SEC (Form 13F); the 25 largest follow.
| Manager | Shares | Value | |
|---|---|---|---|
| MPM BIOIMPACT LLC | 10,679,391 | 28M $ | as of Mar 31, 2026 |
| Nextech Invest, Ltd. | 7,419,355 | 19.4M $ | as of Mar 31, 2026 |
| Deep Track Capital, LP | 7,419,355 | 19.4M $ | as of Mar 31, 2026 |
| Soleus Capital Management, L.P. | 6,963,141 | 18.2M $ | as of Mar 31, 2026 |
| Octagon Capital Advisors LP | 5,250,000 | 13.8M $ | as of Mar 31, 2026 |
| Blue Owl Capital Holdings LP | 5,089,015 | 13.3M $ | as of Mar 31, 2026 |
| Avidity Partners Management LP | 4,998,267 | 13.1M $ | as of Mar 31, 2026 |
| FRANKLIN RESOURCES INC | 3,803,338 | 10M $ | as of Mar 31, 2026 |
| MARSHALL WACE, LLP | 2,948,441 | 7.7M $ | as of Mar 31, 2026 |
| TCG Crossover Management, LLC | 2,682,696 | 7M $ | as of Mar 31, 2026 |
| GREAT POINT PARTNERS LLC | 2,238,496 | 5.9M $ | as of Mar 31, 2026 |
| MILLENNIUM MANAGEMENT LLC | 1,424,374 | 3.7M $ | as of Mar 31, 2026 |
| Squadron Capital Management LLC | 1,100,000 | 2.9M $ | as of Mar 31, 2026 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 1,093,894 | 2.9M $ | as of Mar 31, 2026 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 1,000,000 | 2.6M $ | as of Mar 31, 2026 |
| Sio Capital Management, LLC | 917,922 | 2.4M $ | as of Mar 31, 2026 |
| BlackRock, Inc. | 846,696 | 2.2M $ | as of Mar 31, 2026 |
| GEODE CAPITAL MANAGEMENT, LLC | 603,767 | 1.6M $ | as of Mar 31, 2026 |
| Cormorant Asset Management, LP | 529,550 | 1.4M $ | as of Mar 31, 2026 |
| JANE STREET GROUP, LLC | 436,931 | 1.1M $ | as of Mar 31, 2026 |
| ADAR1 Capital Management, LLC | 351,094 | 919.9K $ | as of Mar 31, 2026 |
| GOLDMAN SACHS GROUP INC | 287,299 | 752.7K $ | as of Mar 31, 2026 |
| Woodline Partners LP | 250,088 | 655.2K $ | as of Mar 31, 2026 |
| STATE STREET CORP | 233,507 | 611.8K $ | as of Mar 31, 2026 |
| Seven Fleet Capital Management LP | 190,785 | 499.9K $ | as of Mar 31, 2026 |
Declared shareholders of Context Therapeutics Inc
5 beneficial ownership filings. These stakes do not add up: an asset manager filing aggregates its own funds, already counted above.
| Shareholder | Declared stake | Shares | |
|---|---|---|---|
| Avidity Partners Management LP and 5 others | 8.70 % | 8,302,808 | as of Mar 31, 2026 · SCHEDULE 13G |
| Soleus Capital Master Fund, L.P. and 5 others | 7.60 % | 6,963,141 | as of Mar 31, 2026 · SCHEDULE 13G |
| Octagon Capital Advisors LP and 2 others | 5.70 % | 5,250,000 | as of Mar 31, 2026 · SCHEDULE 13G |
| Blue Owl Capital Holdings LP | 5.54 % | 5,089,015 | as of Mar 31, 2026 · SCHEDULE 13G |
| Great Point Partners, LLC and 2 others | 2.44 % | 2,238,496 | as of Mar 31, 2026 · SCHEDULE 13G |
Cite this page
Titelia. "Fund shareholders of Context Therapeutics Inc". https://titelia.com/en/stocks/context-therapeutics-inc-US21077P1084